Investor Relations
Latest Financial Results
Stock Information
Company Overview
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
view management team view board of directorsContact Information
Investor Relations
Transfer Agent
Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
https://www.computershare.com
Media
Andrea Christopher
Director Corporate Communications
achristopher@auriniapharma.com